Peptx

Biovest International specializes in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. The company is a subsidiary of Accentia Biopharmaceuticals. It has expertise in the area of manufacturing biologics for research and clinical trials. Additionally, the company develops and markets cell culture systems and an automated vaccine manufacturing instrument for production of cell-based materials and therapeutics. Its product BiovaxID, which is used for the treatment of follicular non-Hodgkin's lymphoma has been given the fast-track status by the Food and Drug Administration. The company has a staff of trained professionals that specializes in hollow-fiber technology. It is headquartered in Worcester, Mass.

Nanocopoeia is a specialty research company based in Saint Paul, Minnesota, founded in 2001 and initially focused on medical devices and advanced nano-scale coating processes. With a recent restructuring, the company is now dedicated to enhancing oral-solid drug development through innovative technologies that address low solubility and bioavailability challenges. Led by an experienced executive team, Nanocopoeia aims to create valuable drug products that improve patient safety, compliance, and effectiveness. The company actively seeks partnerships and collaboration to build long-term value in the pharmaceutical industry, emphasizing a commitment to teamwork and innovation. Generated from the website